National Coverage Determination (NCD 110.24): Chimeric Antigen Receptor (CAR) T-cell Therapy


This article tells you that, effective for claims with dates of service on or after August 7, 2019, CMS covers autologous treatment for cancer with T-cells expressing at least one Chimeric Antigen Receptor (CAR) when administered at healthcare facilities: enrolled in the FDA Risk Evaluation and Mitigation Strategies (REMS) and meets specified CMS/FDA criteria. Make sure that your billing staffs are aware of these changes.





Last Updated: 07/22/2021